Trump creates NIH women's health division but keeps existing office

President Donald Trump signed an executive order on Monday creating a Women's Health Division at the National Institutes of Health and a White House Women's Health Task Force. The order, titled "Advancing Women's Health to Improve Outcomes in All Phases of Life," was signed alongside first lady Melania Trump, who called it a "transformative moment" for women's health in America.

The task force will be led by White House chief of staff Susie Wiles, who recently announced she is cancer-free, and Health Secretary Robert F. Kennedy Jr., according to a White House official. Melania Trump pressed the administration to prioritize women's health and set up meetings herself, and she praised the initiative as setting a new standard for women's health in America.

The new NIH division will not replace the agency's Office of Research on Women's Health but will have a broader mandate beyond research. That distinction matters: the order creates a new institutional home for women's health at NIH and a White House coordinating body, but it does not eliminate the existing office. The practical effect depends on how the broader mandate is defined, implemented, and funded — details the evidence does not yet establish.

What the order actually changes is structural. It adds a division and a task force. What it leaves unchanged is the Office of Research on Women's Health, which continues to exist. Whether the new division expands research capacity, duplicates functions, or shifts priorities within NIH is not specified in the available evidence.

Open questions remain: how the new division's broader mandate will be defined and funded relative to the existing office; what specific authorities the White House task force will have and how it will coordinate with the Department of Health and Human Services and NIH; what timelines or deliverables accompany the order; and how the initiative will address the research gaps it aims to close.

For readers, the immediate takeaway is limited. The order establishes new bodies but does not, on the evidence available, change funding levels, research protocols, or care guidelines. The order's impact will depend on implementation choices not yet made public.